Imunon (NASDAQ:IMNN) Announces Quarterly Earnings Results

Imunon (NASDAQ:IMNN) posted its earnings results on Tuesday. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.38, FiscalAI reports.

Here are the key takeaways from Imunon’s conference call:

• Imunon said OVATION 3 is progressing well, with management reiterating that enrollment remains on track and that the company expects to randomize about 80 patients by the end of Q1 2027.
• The company highlighted strong Phase II results for IMNN-001, including a 14.7-month median overall survival benefit in OVATION 2, which management believes supports the drug’s potential in frontline ovarian cancer.
• Management emphasized that the Phase III trial is designed around overall survival as the primary endpoint, with two planned interim analyses and a path that could support a single pivotal-trial BLA filing if successful.
• Imunon acknowledged the challenging biotech funding environment and said it is pursuing bridge financing and cost controls to extend runway while trying to minimize dilution.
• First-quarter 2026 operating cash use was $4.0 million, up from $2.8 million a year ago, largely due to OVATION 3 startup costs, while R&D and G&A expenses were roughly stable year over year.

Imunon Stock Performance

NASDAQ IMNN traded up $0.04 during trading on Thursday, reaching $2.64. 3,748 shares of the company traded hands, compared to its average volume of 74,268. The stock’s 50 day moving average price is $2.97 and its two-hundred day moving average price is $3.46. The company has a market cap of $10.49 million, a price-to-earnings ratio of -0.50 and a beta of 2.04. Imunon has a 1-year low of $2.50 and a 1-year high of $41.22.

Institutional Investors Weigh In On Imunon

An institutional investor recently raised its position in Imunon stock. DRW Securities LLC raised its stake in shares of Imunon, Inc. (NASDAQ:IMNN) by 6.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 58,830 shares of the company’s stock after purchasing an additional 3,803 shares during the quarter. DRW Securities LLC owned 1.92% of Imunon worth $224,000 as of its most recent filing with the Securities and Exchange Commission. 4.47% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Maxim Group set a $10.00 target price on Imunon and gave the company a “buy” rating in a report on Friday, April 17th. Weiss Ratings restated a “sell (e+)” rating on shares of Imunon in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $10.00.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.